07:00 , May 14, 2012 |  BC Week In Review  |  Clinical News

ASM8: Phase IIa data

The double-blind, 3-way crossover, Canadian Phase IIa TPI ASM8-207 trial in 16 patients with allergic asthma showed that once-daily 3 and 7.8 mg inhaled ASM8 administered via a nebulizer significantly reduced allergen-induced LAR from baseline...
07:00 , Oct 10, 2011 |  BC Week In Review  |  Clinical News

ASM8: Completed Phase II enrollment

Pharmaxis completed enrollment of 16 adult asthmatics in a double-blind, placebo-controlled, 3-arm crossover, Canadian Phase II trial evaluating once-daily 3 and 7.8 mg ASM8 for 14 days. Pharmaxis Ltd. (ASX:PXS; Pink:PXSLY), Frenchs Forest, Australia   Product:...
08:00 , Dec 13, 2010 |  BC Week In Review  |  Clinical News

ASM8: Phase II started

Pharmaxis began a double-blind, placebo-controlled, 3-arm crossover, Canadian Phase II trial in 16 adult asthmatics to evaluate once-daily 3 and 7.8 mg ASM8 for 14 days. Pharmaxis Ltd. (ASX:PXS; Pink:PXSLY), Frenchs Forest, Australia   Product: ...
07:00 , Mar 22, 2010 |  BC Week In Review  |  Clinical News

ASM8: Phase IIa data

In the open-label, Canadian Phase IIa TPI ASM8-206 trial in 12 patients, inhaled 8 mg ASM8 once daily for 4 days met the primary endpoint of significantly reducing sputum eosinophil count at 7 and 24...
08:00 , Jan 12, 2009 |  BC Week In Review  |  Clinical News

TPI ASM8: Phase II data

In the double-blind, European Phase II TPI ASM8-205 trial in 18 patients with mild to moderate asthma, inhaled TPI ASM8 once daily for 14 days missed the primary endpoint of an allergen-induced maximum decrease in...
07:00 , Jul 28, 2008 |  BC Week In Review  |  Clinical News

TPI ASM8: Completed Phase I enrollment

Topigen completed enrollment in a double-blind, placebo-controlled, European Phase II (TPI ASM8-205) trial evaluating inhaled TPI ASM8 for 14 days. The study was originally designed to enroll 18 patients. Topigen Pharmaceuticals Inc., Montreal, Quebec   Product:...
08:00 , Feb 4, 2008 |  BC Week In Review  |  Clinical News

TPI ASM8: Phase II started

Topigen began the double-blind, placebo-controlled, European Phase II TPI ASM8-205 trial to evaluate inhaled TPI ASM8 in about 18 patients for 14 days. Topigen Pharmaceuticals Inc., Montreal, Quebec   Product: TPI ASM8   Business: Inflammation   Molecular...
07:00 , May 28, 2007 |  BC Week In Review  |  Clinical News

TPI ASM8: Additional Phase II data

Additional data from a double-blind, Canadian Phase II trial in 17 patients showed that 3 days of once-daily ASM8 significantly reduced eosinophil levels by 49% vs. placebo (p=0.02). The compound also significantly reduced EAR (p=0.03)...
07:00 , Mar 12, 2007 |  BC Week In Review  |  Clinical News

TPI ASM8: Phase II started

Topigen started a placebo-controlled, double-blind, Canadian Phase II trial in 60 patients who will receive either 250 or 500 µg of inhaled TPI ASM8 or placebo. Topigen Pharmaceuticals Inc., Montreal, Quebec   Product: TPI ASM8...
07:00 , Jul 24, 2006 |  BC Week In Review  |  Clinical News

TPI-ASM8: Preliminary Phase II data

Preliminary data from a double-blind, placebo-controlled, Canadian Phase II trial in 17 patients showed that inhaled TPI-ASM8 was safe and well tolerated. TPI-ASM8 also reduced eosinophil counts. Topigen Pharmaceuticals Inc., Montreal, Quebec   Product: TPI-ASM8...